LC-MS/MS analysis of two breast cancer cell lines, MDA-MB-231 and SCP2 cells

Bone is the most common metastasis site in patients with breast cancer, and approximately up to 80% of patients with advanced breast cancer (BC) develop bone metastasis (BM), which leads to a worse prognosis with a median survival of 16 months and skeletal-related events (SREs), including severe bone pain, pathological fracture, hypercalcemia and lethal complications. Using quantitative proteomics mass-spectrometry (MS) analysis of low bone-metastatic BC cells (MDA-MB-231) and high bone-metastatic BC cells (SCP2), we identified an unreported breast cancer (BC) cells–secreted microprotein, LINC00263-P, encoded by lincRNA LINC00263 and clinically associated with BC bone-tropism.